Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
about
Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failureRegulation of nephron water and electrolyte transport by adenylyl cyclasesProtection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retentionThe nonglycemic actions of dipeptidyl peptidase-4 inhibitorsAnti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.Caffeine-induced diuresis and natriuresis is independent of renal tubular NHE3GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study.Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trialDipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome.Effects of glucagon-like peptide-1 receptor agonists on renal functionLinagliptin as add-on therapy to insulin for patients with type 2 diabetesIncrease in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.Cardiovascular effects of gliptins.Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach.The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Is there a role for the incretin system in blood pressure regulation?Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease.DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.GLP-1 Agonists and Blood Pressure: A Review of the Evidence.Novel developments in differentiating the role of renal and intestinal sodium hydrogen exchanger 3.The physiological role of glucagon-like peptide-1 in the regulation of renal function.Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure.Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin.Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.Urinary adenosine excretion in type 1 diabetes.Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic.Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flowEndogenous Glucagon-Like Peptide-1 as a Potential Mediator of the Resolution of Diabetic Kidney Disease following Roux en Y Gastric Bypass: Evidence and Perspectives
P2860
Q26829634-46326FBC-F4E9-47CD-A5C5-6A0E6228C001Q27023655-70D0108A-7BF7-441C-8606-E1523D35D5DCQ30390165-A7E9055A-B931-4663-97B7-07038AEF86D3Q30717371-E7F996C6-8251-4591-BBFD-F97B3474A517Q34029715-907DE02E-1014-4C2E-A291-21835FBFA59BQ35784692-347493D4-83CB-4CA5-8E55-1514B314FD73Q36104511-76ED1080-D55B-4E5E-B72D-521D0F4871C8Q36406821-F218860A-DAD8-4D98-938B-987207C3FF51Q36976775-62E86DA1-B4DD-4941-9583-C09A51D06234Q36990093-F055E968-A522-41AE-B3A4-F8A70F546588Q37177528-A7AD72D4-151B-40A0-962F-FC78D78962BAQ37232679-5A4936EF-60CB-41AE-85EC-6A3D41199299Q37281205-62AD4B8B-4C5D-4A5A-B19E-3B768DF854F9Q37575461-32A6BA82-E2DE-455E-ACAF-09510CFA482BQ38072259-164CAA47-1F31-4679-BA89-3D79FB1C77E8Q38119146-36EF289E-6F90-4132-9E00-9C77246680E0Q38174491-68077D96-19DD-4799-B95E-5C754A9A71E5Q38182499-B094CC2E-41C5-457A-B026-AC40D1799315Q38236209-78B29862-9EAC-4721-ABF1-03DD1B9C511CQ38236210-E6E38AAB-F5E5-4742-99AF-EE1BED9E65ADQ38413395-85F86E64-B51E-489C-88B0-40AE64F67113Q38709406-C672E84F-D281-4BD1-91D2-5EC387FA8158Q38979089-C467B978-3FA0-4E64-B444-A199D02B69DDQ40976120-25113B6F-BF16-4665-B715-8D39048772F2Q42050075-C19D591F-4F1B-48BD-AD89-646D819F06BEQ42848424-8F79A528-BD78-432F-B66C-BC07EE834A50Q46099197-F5FD55E5-07F0-4F0E-9B06-08FC0F2E338EQ46770322-8CEDFCF5-D302-40BF-A889-9A11343E395FQ47265349-BBFF23DB-0BA5-4F8D-BAAC-FACE7A9B739AQ47660883-01B6358B-32B8-41D3-B506-B1B8B7A3DF3CQ48141985-360E08B2-FD64-4617-AA1B-1894D937090FQ49592715-C1C7896B-AE13-43EC-9BF9-39F86461F5AAQ49824014-D82A4230-DFF8-45EC-BC93-996F7288D2AAQ50746947-EF9D7C4A-DAE5-4EBA-823F-BE4F498A58E7Q50974989-8373EE19-4A49-48EB-A485-BF35FD0E9887Q58447525-26DD312F-7FF5-4607-8D39-E24163681102Q59043926-E6AC63B8-B3C5-47C4-839E-0D0A12EC90FA
P2860
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Natriuretic effect by exendin- ...... in obese type 2 diabetic mice.
@ast
Natriuretic effect by exendin- ...... in obese type 2 diabetic mice.
@en
type
label
Natriuretic effect by exendin- ...... in obese type 2 diabetic mice.
@ast
Natriuretic effect by exendin- ...... in obese type 2 diabetic mice.
@en
prefLabel
Natriuretic effect by exendin- ...... in obese type 2 diabetic mice.
@ast
Natriuretic effect by exendin- ...... in obese type 2 diabetic mice.
@en
P2093
P2860
P50
P1476
Natriuretic effect by exendin- ...... in obese type 2 diabetic mice.
@en
P2093
Maria Gerasimova
Michael Rose
Volker Vallon
P2860
P304
P356
10.1152/AJPRENAL.00259.2012
P577
2012-07-25T00:00:00Z